Phase I/II, open-label, pharmacokinetic and safety study of a novel protease inhibitor (BMS 232632, atazanavir, ATV, Reyataz) in combination regimens in antiretroviral therapy (ART)-naive and -experienced HIV-infected infants, children, and adolescents

Trial Profile

Phase I/II, open-label, pharmacokinetic and safety study of a novel protease inhibitor (BMS 232632, atazanavir, ATV, Reyataz) in combination regimens in antiretroviral therapy (ART)-naive and -experienced HIV-infected infants, children, and adolescents

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2016

At a glance

  • Drugs Atazanavir (Primary) ; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms IMPAACT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jul 2010 Response rates (HIV RNA <50 copies per/mL) were reported for the atazanavir+ ritonavir combination treatment group in a Bristol-Myers Squibb media release.
    • 05 Jul 2010 Status changed from active, no longer recruiting to completed according to BMS media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top